DailyIQ
|
Sector:HealthcareAll sectors
Last updated2 minutes ago

JNJ·Johnson & Johnson

$275.15
-3.28 (-1.18%)
Market Closed (Overnight)$276.53+1.38 (+0.50%)
High
$278.80
Open
$275.13
Market Cap
669.98B
52W High
$281.07
Low
$274.75
P. Close
$275.15
P/E
31.85
52W Low
$173.33
Fwd P/E
22.36
DailyIQ Est.
$286.38
Inst. Ownership
37.1%
Short Interest
0.89%
Days to Cover
3.3
Technical Score (1D)
95
BUY
News Sentiment
49
MIXED
Johnson & Johnson’s share price now implies an almost 12 % annual revenue growth over the next three years, a pace that far exceeds the company’s current 2026 sales guidance of 7.0‑7.6 %. The valuation, built on a modest 6.7 earnings multiple, is therefore highly sensitive to any revision of top‑line expectations; a downgrade could trigger a re‑pricing in the next trading week. The gap between market expectations and management’s outlook is already a source of risk, and investors should watch for any guidance update that narrows the implied growth gap. In the same window, AbbVie’s Phase III bispecific T‑cell engager etentamig achieved a 74 % objective response rate in relapsed or refractory multiple myeloma, surpassing JNJ’s Tecvayli’s 45.7 % rate. This superior efficacy threatens to erode JNJ’s market share in that therapeutic area, potentially impacting its future revenue streams. The safety profile of etentamig also appears favorable, which could accelerate its regulatory approval and market uptake. The combination of a valuation built on higher growth expectations and a competitive threat in a key oncology segment suggests that JNJ’s near‑term performance will hinge on both guidance revisions and the pace of AbbVie’s product launch. Watch for the next earnings call for any upward revision of sales guidance and for AbbVie’s regulatory decision on etentamig, as both events could materially influence JNJ’s short‑term outlook.
Earnings Summary
Johnson & Johnson is a global healthcare conglomerate with a dual focus on Innovative Medicine and MedTech, delivering prescription drugs across immunology, oncology, neuroscience, and cardiovascular areas while also supplying a broad array of medical devices to hospitals and retailers. Operating within the highly competitive drug manufacturing sector, J&J leverages its extensive R&D pipeline to sustain diversified revenue streams. In the most recent two quarters, the company posted EPS of $2.77 in Q1 2025 and $2.77 again in Q2 2025, both beating analyst estimates of $2.58 and $2.68 respectively, while revenue rose from $21.89 billion to $23.74 billion, a 8.4% increase that outpaced prior quarter growth of 6.3%. The trend continued into Q3 2025 with EPS of $2.80 versus an estimate of $2.76 and revenue of $23.99 billion, maintaining a steady upward trajectory. Historically, J&J has shown a consistent YoY revenue growth of roughly 5–6% over the past four quarters, with EPS consistently beating estimates in three of the last four periods, underscoring a pattern of solid earnings performance even as revenue growth moderates. Recent news highlights include FDA approvals for MIMRYLO and Imaavy, expanding the rare‑disease portfolio, and Chinese approval for oral Icotyde, which could shift patients from injectable Tremfya to an oral therapy; these regulatory wins are likely to bolster future sales. Investors should watch for the next earnings call to gauge any revisions to sales guidance, the timing of the Imaavy launch, and early sales data for Icotyde, as these factors will be key catalysts that could influence J&J’s short‑term outlook.}}

EPS

EstBeatMiss
$2.35$2.51$2.66$2.82$2.97Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.42 - -
Q2'26$2.87$2.90+0.9%
Q1'26$2.88$2.70-6.4%
Q4'25$2.46$2.46-0.1%
Q3'25$2.76$2.80+1.5%
Q2'25$2.68$2.77+3.2%

Revenue

EstBeatMiss
$23.5B$24.1B$24.7B$25.3B$25.8BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$25.6B - -
Q2'26$25.3B$25.3B+0.0%
Q1'26$25.0B$24.1B-3.9%
Q4'25$24.4B$24.6B+0.7%
Q3'25 - $24.0B -
Q2'25 - $23.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

JNJ Stock Snapshot

BUY95/100
$276.53+$1.38 (0.5%)
Market cap
669.98B
P/E ratio
31.9
Day range
$274.75 – $278.80
News sentiment
49/100 · Neutral
Analyst target
$275.64 (-0.3%)
Consensus
Buy · 33 analysts
52-week range+59.5% off low · -1.6% from high
$173.33$281.07
Price $276.53 DailyIQ Est. $286.38

Price is near its 52-week high, and the momentum read backs that positioning up. Coverage is deep enough that new information gets priced quickly, so surprises tend to be macro rather than fundamental.

Reverse DCF

What growth is priced into JNJ?

RICH

At today's price, Johnson & Johnson needs to grow free cash flow about 8.8% a year for the next 10 years to justify its valuation at a 6.37% cost of capital. Over its actual history it has compounded free cash flow at 3.9% a year, so the market is asking for 5.0 percentage points above its own delivered rate. On that basis JNJ looks priced above what its own growth record supports.

Implied FCF growth
8.8%
Historical FCF CAGR
3.9%
Growth gap
+5.0 pts
Verdict
RICH
Discount rate (WACC)
6.37%
Beta
0.37

Behaviour On Record

What JNJ's own history says about today's numbers

Realized volatility (21d)
21.3% 87th pct
Below its peak
-0.0%
vs 200-day average
+18.2%
Up days (1y)
53%

Johnson & Johnson is currently running 21.3% annualised volatility over the last 21 sessions. Measured against JNJ's own 13 years of daily returns rather than a market-wide average, that is the 87th percentile — elevated for this stock, against a typical reading of 14.7%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

JNJ is at its running peak. Across 12 full years on file its median worst-drawdown-in-a-year was -13.5%, with the deepest at -26.0% in 2020 — so highs have historically been given back before they were extended.

Price sits +18.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 96th percentile — a wider gap than this stock usually carries. Over the past year JNJ closed higher on 53% of sessions, and it is currently 1 session into a falling streak.

On September specifically: over 13 years of records, JNJ finished the month higher 5 of 13 times, with a median return of -0.5% and an average of -0.2%. Its strongest month historically has been June at +2.3% on average, its weakest May at -0.8%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: JNJ has opened more than 2% away from the prior close in 15 of 3,269 sessions (0.5% of the time), with the largest gaps running +3.3% and -4.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, JNJ moved an average of 1.0% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.2% and a largest of +1.5%.

All figures computed from 3,270 daily closes between 2013-09-05 and 2026-09-04, split-adjusted, recomputed daily. Percentiles are against JNJ's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of JNJ's sector?

Johnson & Johnson sits in the Health Care sector, currently ranked 2nd of 11 GICS sectors by relative-strength rotation score (weakening).

Sector rank
#2 of 11
Sector state
Weakening
Sector rotation score
90

Options Market

What is the options market pricing for JNJ?

CallsPuts

For Johnson & Johnson's nearest expiry (2026-09-11, 6 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.76), with at-the-money implied volatility around 36.2%. The options market is pricing roughly a ±3.8% move by that expiry — a range of about $258.07–$278.73.

Put/call ratio (2026-09-11)
0.76
ATM implied volatility
36.2%
Total open interest
4,402
Expected move by 2026-09-11
±3.8% ($258.07–$278.73)

Analyst Rating Changes

Are analysts turning bullish or bearish on JNJ?

UBS most recently reiterated its rating on Johnson & Johnson to Buy on Sep 2, 2026 with a price target of $320 (from $280). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
UBS — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 2, 2026UBSMaintainedBuy$280 → $320
Aug 6, 2026GuggenheimMaintainedBuy$270 → $287
Aug 3, 2026Wells FargoMaintainedOverweight$272 → $282
Jul 17, 2026GuggenheimReiteratedBuy$270
Jul 16, 2026Raymond JamesMaintainedOutperform$258 → $265
Jul 16, 2026RBC CapitalReiteratedOutperform$287
Jul 16, 2026Wells FargoMaintainedOverweight$263 → $272
Jul 16, 2026Morgan StanleyMaintainedOverweight$284 → $294
Jul 13, 2026TD CowenMaintainedBuy$250 → $300
Jul 13, 2026RBC CapitalMaintainedOutperform$265 → $287
Jul 10, 2026B of A SecuritiesMaintainedNeutral$254 → $263
Jul 8, 2026Morgan StanleyMaintainedOverweight$283 → $284

JNJ Competitive Positioning

Johnson & Johnson (JNJ) is tracked alongside these names in Drug Manufacturers - General on DailyIQ — ranked by market cap, with today's move alongside.

Held by These ETFs

JNJ is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.